martes, 21 de marzo de 2017

NGC Update Service: March 20, 2017 | Announcements

NGC Update Service: March 20, 2017



Matrix Tool

The Matrix Tool feature allows for easy retrieval and exporting of relevant content of interest. Select attributes to filter NGC summary content and generate a matrix that fits your needs. View the Video Tutorial.

Conference News

Donald Berwick Message to E-GAPPS III Conference: Available via live Webcasting, Tuesday, March 21, 1pm EDST. G-I-N North America and the Section on Evidence Based Health Care of the New York Academy of Medicine are excited to announce that a taped message from Donald Berwick, President Emeritus of the Institute for Healthcare Improvement and former Administrator of the U.S. Centers for Medicare and Medicaid Services. The message will be shown to the E-GAPPS III conference at 1pm EDST, March 21 and will be accessible through live webcasting at the following link:
Dr Berwick's comments will kick off the final segment of the E-GAPPS Conference, which will feature free and open dialogue among all conference attendees, including presenters, moderators and participants, in an 'open space' format. Some other segments of the conference will also be accessible via the same link. More information on E-GAPPS III is available via:

U.S. Food and Drug Administration (FDA) Advisory

March 15, 2017Viberzi (eluxadoline): FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, FDA is working with the Viberzi manufacturer, Allergan, to address these safety concernsars.

AHRQ Announces Funding Opportunity for Developing Measures of Shared Decisionmaking

A new funding opportunity announcement from AHRQ solicits applications for research projects to develop, test and evaluate measures of shared decisionmaking for research conducted in clinical settings. Shared decisionmaking is a collaborative process in which patients and members of their clinical team make health care decisions that are informed by scientific evidence as well as patients' values and preferences. Each project is expected to produce valid and reliable measures of shared decisionmaking, along with instructions for implementing the measures and documentation on the development, testing and evaluation of the measures. The maximum cost for each project is $500,000 per year and $1.5 million for up to three years.

Health Awareness Topics: March 2017

How to Participate

Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

No hay comentarios: